HELP

NASDAQ 已收盘

Helus Pharma

6.78 USD
▼-0.11-1.60%
盘后 6.92 +2.06%
2026-11-19
市值
$446.40M
市盈率
—
EPS
-4.41
股息率
—
52 周区间
3.76 – 15.15
成交量
2.06M
Beta
0.62
目标价
46.32
52W 低 3.7652W 高 15.15
价格走势

公司简介

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’s preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strat...

关联新闻